Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 1;11(1):e210046.
doi: 10.1530/ETJ-21-0046.

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

Furio Pacini  1 , Dagmar Fuhrer  2 , Rossella Elisei  3 , Daria Handkiewicz-Junak  4 , Sophie Leboulleux  5 , Markus Luster  6 , Martin Schlumberger  5 , Johannes W Smit  7
Affiliations

2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?

Furio Pacini et al. Eur Thyroid J. .

Abstract

Modern use of post-operative radioactive iodine (RAI) treatment for differentiated thyroid cancer (DTC) should be implemented in line with patients' risk stratification. Although beneficial effects of radioiodine are undisputed in high-risk patients, controversy remains in intermediate-risk and some low-risk patients. Since the last consensus on post-surgical use of RAI in DTC patients, new retrospective data and results of prospective randomized trials have been published, which have allowed the development of a new European Thyroid Association (ETA) statement for the indications of post-surgical RAI therapy in DTC. Questions about which patients are candidates for RAI therapy, which activities of RAI can be used, and which modalities of pre-treatment patient preparation should be used are addressed in the present guidelines.

Keywords: differentiated thyroid cancer; indications; radioiodine; treatment.

PubMed Disclaimer

References

    1. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992–2006. Thyroid 201121125–134. (10.1089/thy.2010.0021) - DOI - PMC - PubMed
    1. Dal Maso L, Tavilla A, Pacini F, Serraino D, van Dijk BAC, Chirlaque MD, Capocaccia R, Larrañaga N, Colonna M, Agius Det al.Survival of 86,690 patients with thyroid cancer: a population-based study in 29 European countries from EUROCARE-5. European Journal of Cancer 201777140–152. (10.1016/j.ejca.2017.02.023) - DOI - PubMed
    1. Leenhardt L, Bernier MO, Boin-Pineau MH, Conte Devolx B, Maréchaud R, Niccoli-Sire P, Nocaudie M, Orgiazzi J, Schlumberger M, Wémeau JLet al.Advances in diagnostic practices affect thyroid cancer incidence in France. European Journal of Endocrinology 2004150133–139. (10.1530/eje.0.1500133) - DOI - PubMed
    1. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, Bardet S, Leenhardt L, Bastie D, Schvartz Cet al.Strategies of radioiodine ablation in patients with low-risk thyroid cancer. New England Journal of Medicine 20123661663–1673. (10.1056/NEJMoa1108586) - DOI - PubMed
    1. Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready Ret al.Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. New England Journal of Medicine 20123661674–1685. (10.1056/NEJMoa1109589) - DOI - PubMed